On July 16, Erasca declined 5.27% in regular trading, trading around $20.005/share, with turnover of approximately $39.43 million.

The decline was primarily driven by the completion of the company's upsized public offering of over 36.1 million common shares priced at $17.50 each, generating gross proceeds of approximately $632.5 million. The offering size was significantly expanded from the initially announced $500 million plan, and included approximately 4.7 million additional shares from the full exercise of the underwriters' overallotment option. Notably, the $17.50 offering price represents a meaningful discount to the current trading level, intensifying market concerns over substantial equity dilution.

Erasca stated that net proceeds will fund research and development of its product candidates, including the advancement of ERAS-0015 toward registration-enabling trials in lung cancer and a Phase 3 pancreatic cancer study planned for initiation in the first half of next year.

Erasca is a clinical-stage precision oncology company focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)